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The Commission on Intellectual Property, Innovation and Public Health (CIPIH) was given the task of reviewing existing research and development (R&D) efforts, examining the role of intellectual prope e erty (IP) in stimulating innovation, and to make concrete proposals for action by national and international stakeholders, both public and private, to encourage R&D for diseases that disproportione e ately affect developing countries. The Commission focussed exclusively on the application of IP to pharmaceuticals, and did not address the public health ime e plications of copyright law, or genomic patents, which are covered elsewhere in this issue.
The report 1 presents a wealth of evidence and analysis in support of the view that the current system of drug dee e velopment is fundamentally flawed and leaves huge health needs unmet, because of its reliance on patents and commercial incentives for the priorityesetting and financing of medical R&D. The report calls for improved mechanisms that proe e mote research that responds to patients' needs, and that ensure access to innovae e tions for all. However, it fails to provide alternatives and concrete new proposals.
Many of the data presented in the report illustrate the urgent need for change. I will discuss some of the Come e mission's more salient conclusions, on intellectual property rights, international trade, access to medicines, and global frameworks.
Intellectual property rights
The report recognizes that IP is a means and not an end. It concludes that IP is irrelevant in stimulating innovation in developing countries where markets have limited purchasing power, confirming the same finding by the UK Commise e sion on Intellectual Property Rights in September 2002. 2 The report says: "There is no evidence that the implee e mentation of the TRIPS Agreement in developing countries will significantly boost R&D in pharmaceuticals on Type The report also points out that even in regions with strong IP protection, innovation results are declining. In the USA for example, medical R&D spende e ing has doubled between 1995 and 2002, while in the same period, the registration of new products has declined, as well as the therapeutic significance of products reaching the market. In other words, although worldwide patent standards have been strengthened since 1995 as a result of the TRIPS Agreement, and global spending on medical R&D has increased, pharmaceutical innovation has declined both in quantity and quality.
Furthermore, the report draws ate e tention to the fact that patents can actue e ally hamper innovation, by blocking followeon research or access to research tools. The CIPIH identifies patent pools, compulsory licensing, and the applicae e tion for research exemptions as potential solutions to overcome barriers caused by patenting.
International trade and competition
The report warns against trade agreee e ments that include soecalled "TRIPSe plus" measures. The Commission cone e cludes: "Bilateral trade agreements should not seek to incorporate TRIPSe plus protection in ways that may reduce access to medicines in developing coune e tries." (Recommendation 4.21).
1 "Data exclusivity" is one example of a TRIPSeplus provision often included in bilateral trade agreements with the US. The report offers much awaited clarity on issues related to the protection of data submitted by companies to obtain marketing approval for new medicines. WTO Members are obliged to protect undisclosed test or other data against unfair commercial use. But this does not imply property rights, nor a right to pree e vent others from using the data, or from relying on the data for the marketing approval of the same product by a third party -except where unfair, dishonest commercial practices are involved.
Developing countries have been pressured during bilateral talks to accept TRIPSeplus provisions including data exclusivity rules that would delay the introduction of generic medicines.
The Commission's analysis here may help, but it is doubtful whether it will be enough. Médecins sans Frontières (MSF) regrets that the Commission fails to support the call for an international moratorium on TRIPSeplus provisions in bilateral and regional trade agreements that may hamper access to medicines. Nor does the report suggest a role for WHO on this issue.
Access to medicines
The Commission analyses the medical innovation cycle according to three components: discovery, development, and delivery. The report stresses that innovation is only meaningful when people can have access to the results of the innovation. This is obviously not the case when new drugs are priced out of reach of the people who need them.
The report recommends that gove e ernments should create competitive envie e ronments in their countries, as competie e tion is the key means of driving prices down and improving access to medie e cines. Yet the TRIPS Agreement -ime e plemented worldwide in 2005 -was designed precisely to impede countries from doing so. Secondeline acquired immunodeficiency syndrome (AIDS) medicines illustrate the consequences of such protectionism. These new antiretroe e virals are priced far beyond the reach of the people, as they are mostly available from the patent holder only -if at all -in the countries that need them most.
In response to such dilemmas, the report recommends the use of compule e sory licensing to increase generic compee e tition and ensure access to more afforde e able products. It also calls on companies Special Theme -Intellectual Property Rights and Public Health Perspectives to work towards reducing prices. This appeal is not new. MSF has collected the evidence to show that companies are immune to such pleas when there is no generic competition to convince them otherwise. 3 The call for equitable price e ing is unlikely to be more than wishful thinking, unless countries develop the ability to make it happen.
Global plans and global frameworks
The Commission recommends that WHO develop a global plan of action to secure enhanced and sustainable funding for developing affordable and accessible products that address diseases that disproportionately affect developing countries. It urges WHO to continue monitoring from a public health point of view the impact of IP on the devele e opment of new products, as well as on access to medicines. It calls for action to ensure that health technologies are adapted to needs of people in develope e ing countries, and draws attention to the fact that innovation and access are key in tackling both communicable and none communicable diseases. Recommendae e tion 4.5, for example, reads: "Policies for biomedical innovation must take account of the fact that health systems in many developing countries remain resourceeconstrained. Policies must eme e phasize affordable innovations adapted to the realities of healthecare delivery in developing countries, and covering appropriate technologies for the diage e nosis, prevention and treatment of both communicable and noncommunicable diseases. Mechanisms for promoting such adaptive research in a systematic way must be improved." This offers a unique and timely ope e portunity to build on the CIPIH's work. In the words of the sponsors of the resoe e lution: "This resolution is a response to a growing concern over the inadequacy of the current global system for supporting innovation in new medicines and other health technologies, as well as concern about the impact of an increasing pere e centage of people without access to ese e sential medicines and other technologies for health care, both in terms of their financial affordability and availability.
The resolution seeks the establishe e ment of a global framework for supe e porting essential medical research and development predicated upon the prine e ciple of equitable sharing of the costs of research and development, and incentives to invest in useful research and develope e ment in the areas of patients' need and public interest. The process to carry this forward include the creation of a worke e ing group of interested Member States … . As the lead global agency on health needs, WHO plays a crucial role in priority setting and the development of policy recommendations on how priore e ity research can be carried out." 4 One way of ensuring that priority research gets done is through a medical R&D treaty. Here, the CIPIH report says: "Recognizing the need for an ine e ternational mechanism to increase global coordination and funding of medical R&D, the sponsors of the medical R&D treaty proposal should undertake further work to develop these ideas so that gove e ernments and policy makers may make an informed decision." WHO is welle placed to take up this recommendation, and the next World Health Assembly offers an opportunity to do so.
Conclusions
The report contains a thorough analysis on the shortcomings of the current syse e tem for R&D. Dramatic change in the way health R&D is approached is long overdue.
However, the Commission's recome e mendations are somewhat disappointe e ing. Although many are appropriate, they lack teeth, or novelty. 2, 5 I am left with the impression that the Commise e sion got stuck tinkering in the margins of a fundamentally flawed system, lacking the courage -or the power -to propose bold changes. This may be a reflection of the constitution of the Commission and the strong pressure exerted upon it by the pharmaceutical industry. 6 That the TRIPS Agreement is today's predominant international model for ene e couraging innovation is not questioned anywhere. Instead the Commission appeals to the pharmaceutical industry to avoid filing or enforcing patents in loweincome countries, and to grant voluntary licences. This is a somewhat naive recommendation in the light of the fact that the same industry has invested three decades of intense lobbying for the establishment of the TRIPS Agreee e ment. As soon as the CIPIH report was published, the International Federation of Pharmaceutical Manufacturers' Ase e sociation issued a statement on behalf of the industry rejecting any calls for weakening of IP systems. 7 Nevertheless, one message comes through loud and clear from the CIPIH, and that is the need for governments to play a more proactive role to ensure health R&D meets real needs, and that products are available and accessible. Countries should not passively assume that recent partnerships devoted to the development of drugs -no matter how promising some of these initiatives look -constitute a sufficient response. Instead, the Commission urges governe e ments to provide stronger commitments and sustained efforts to address the research gaps identified in this report. The report also recommends that gove e ernments prioritize health care, and ensure that pricing is consistent with their public health policies. In the words of the Commission "Access to drugs cane e not depend on the decisions of private companies but is also a government responsibility". 1 The health ministers who meet in May at the World Health Assembly to discuss the CIPIH report can do just this. This report deserves a strong debate, and followeup action. Médecins Sans Frontières urges governments to take up this challenge, and fulfil what the Commission is right in calling a "moral imperative". O Competing interests: none declared.
